Gil-Perotin, S.
Bernad, L.
Reddam, S.
Ferrer-Pardo, C.
Navarro-Quevedo, S.
SolĂs-Tarazona, L.
Funding for this research was provided by:
Instituto de Salud Carlos III (JR20/00033)
Article History
Received: 5 August 2022
Accepted: 25 October 2022
First Online: 29 October 2022
Competing interests
: SGP is funded by Health Institute Carlos III (ISCIII) with a Juan Rodes contract (JR20/00033). SGP has received speaker honoraria from Sanofi, Roche, Merck, and Biogen, and has been in the advisory board for Merck. The other authors have nothing to disclose.